JP7239575B2 - サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 - Google Patents
サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 Download PDFInfo
- Publication number
- JP7239575B2 JP7239575B2 JP2020522785A JP2020522785A JP7239575B2 JP 7239575 B2 JP7239575 B2 JP 7239575B2 JP 2020522785 A JP2020522785 A JP 2020522785A JP 2020522785 A JP2020522785 A JP 2020522785A JP 7239575 B2 JP7239575 B2 JP 7239575B2
- Authority
- JP
- Japan
- Prior art keywords
- autonomously
- cells
- cell
- seq
- bcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091008875 B cell receptors Proteins 0.000 title claims description 96
- 238000000034 method Methods 0.000 title claims description 29
- 230000027455 binding Effects 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 10
- 230000009870 specific binding Effects 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 64
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 36
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 34
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 32
- 210000003719 b-lymphocyte Anatomy 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 28
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 15
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 102100035634 B-cell linker protein Human genes 0.000 description 7
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 208000012526 B-cell neoplasm Diseases 0.000 description 5
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 5
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 4
- 102000001183 RAG-1 Human genes 0.000 description 4
- 108060006897 RAG1 Proteins 0.000 description 4
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 4
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010004469 allophycocyanin Proteins 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 101710083670 B-cell linker protein Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17001167 | 2017-07-07 | ||
| EP17001166.2 | 2017-07-07 | ||
| EP17001166 | 2017-07-07 | ||
| EP17001167.0 | 2017-07-07 | ||
| EP18162666.4A EP3424527A1 (de) | 2017-07-07 | 2018-03-19 | Diagnostisches verfahren |
| EP18162666.4 | 2018-03-19 | ||
| PCT/EP2018/068316 WO2019008128A1 (de) | 2017-07-07 | 2018-07-05 | Diagnostisches verfahren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527727A JP2020527727A (ja) | 2020-09-10 |
| JP2020527727A5 JP2020527727A5 (enExample) | 2021-08-12 |
| JP7239575B2 true JP7239575B2 (ja) | 2023-03-14 |
Family
ID=64500047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522786A Active JP7271532B2 (ja) | 2017-07-07 | 2018-07-05 | 生物学的結合分子 |
| JP2020522785A Active JP7239575B2 (ja) | 2017-07-07 | 2018-07-05 | サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522786A Active JP7271532B2 (ja) | 2017-07-07 | 2018-07-05 | 生物学的結合分子 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11591391B2 (enExample) |
| EP (4) | EP3424528A1 (enExample) |
| JP (2) | JP7271532B2 (enExample) |
| CA (1) | CA3070848A1 (enExample) |
| WO (2) | WO2019008129A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424528A1 (de) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Biologische bindemoleküle |
| US20220356244A1 (en) * | 2019-05-02 | 2022-11-10 | Ava Lifescience Gmbh | Method for selecting biological binding molecules |
| CA3148214A1 (en) * | 2019-05-02 | 2020-11-05 | Ava Lifescience Gmbh | Antigent binding domains and uses therefor |
| EP3733709A1 (de) * | 2019-05-02 | 2020-11-04 | AVA Lifescience | Biologische bindemoleküle |
| IL310901A (en) * | 2021-08-18 | 2024-04-01 | Univ Pennsylvania | Compositions and methods for chimeric antigen receptors specific to b cell receptors |
| JP2025508389A (ja) | 2022-02-10 | 2025-03-26 | サインエイバイオソリューションズ ゲーエムベーハー | 慢性リンパ性白血病のｂ細胞受容体を標的とする抗体及びその使用 |
| EP4227321A1 (en) * | 2022-02-10 | 2023-08-16 | AVA Lifescience GmbH | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll |
| CA3262006A1 (en) * | 2022-07-25 | 2024-02-01 | Sinabiosolution Gmbh | Humanized chimeric antigen receptors targeting the B-lymphocyte receptor in chronic lymphocytic leukemia and their uses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020526590A (ja) | 2017-07-07 | 2020-08-31 | アー・ファウ・アー ライフサイエンス ゲー・エム・ベー・ハーＡＶＡ Ｌｉｆｅｓｃｉｅｎｃｅ ＧｍｂＨ | 生物学的結合分子 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| JP6401060B2 (ja) | 2012-02-24 | 2018-10-03 | アッヴィ・ステムセントルクス・エル・エル・シー | 抗ｓｅｚ６抗体及び使用方法 |
| WO2014179714A1 (en) * | 2013-05-03 | 2014-11-06 | The Board Of Regents Of The University Of Texas System | Generating peptoid vaccines |
| BR112016004242A8 (pt) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
-
2018
- 2018-03-19 EP EP18162672.2A patent/EP3424528A1/de not_active Withdrawn
- 2018-03-19 EP EP18162666.4A patent/EP3424527A1/de not_active Withdrawn
- 2018-07-05 JP JP2020522786A patent/JP7271532B2/ja active Active
- 2018-07-05 CA CA3070848A patent/CA3070848A1/en active Pending
- 2018-07-05 EP EP18746104.1A patent/EP3615073A1/de active Pending
- 2018-07-05 EP EP18746103.3A patent/EP3615072A1/de active Pending
- 2018-07-05 JP JP2020522785A patent/JP7239575B2/ja active Active
- 2018-07-05 US US16/625,756 patent/US11591391B2/en active Active
- 2018-07-05 US US16/625,754 patent/US11634487B2/en active Active
- 2018-07-05 WO PCT/EP2018/068317 patent/WO2019008129A1/de not_active Ceased
- 2018-07-05 WO PCT/EP2018/068316 patent/WO2019008128A1/de not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020526590A (ja) | 2017-07-07 | 2020-08-31 | アー・ファウ・アー ライフサイエンス ゲー・エム・ベー・ハーＡＶＡ Ｌｉｆｅｓｃｉｅｎｃｅ ＧｍｂＨ | 生物学的結合分子 |
Non-Patent Citations (3)
| Title |
|---|
| BOJARCZUK, K. et al.，B-cell receptor signaling in the pathogenesis of lymphoid malignancies，Blood Cells, Molecules and Diseases，2015年，Vol.55，pp.255-265 |
| MINDEN, M. D. et al.，Chronic lymphocyic leukaemia is driven by antigen-independent cell-autonomous signalling，Nature，2012年09月13日，Vol.489，pp.309-312 |
| MINICI, C. et al.，Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia，nature communications，2017年06月09日，Vol.8, Article number: 15746，pp.1-12 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200199225A1 (en) | 2020-06-25 |
| US11591391B2 (en) | 2023-02-28 |
| CA3070847A1 (en) | 2019-01-10 |
| CA3070848A1 (en) | 2019-01-10 |
| WO2019008129A1 (de) | 2019-01-10 |
| JP2020527727A (ja) | 2020-09-10 |
| EP3424528A1 (de) | 2019-01-09 |
| EP3615072A1 (de) | 2020-03-04 |
| JP2020526590A (ja) | 2020-08-31 |
| EP3615073A1 (de) | 2020-03-04 |
| US11634487B2 (en) | 2023-04-25 |
| US20200209246A1 (en) | 2020-07-02 |
| EP3424527A1 (de) | 2019-01-09 |
| JP7271532B2 (ja) | 2023-05-11 |
| WO2019008128A1 (de) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7239575B2 (ja) | サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法 | |
| US20190077872A1 (en) | Method for enhancing humoral immune response | |
| JP2024096892A (ja) | 生物学的結合分子 | |
| US20240141038A1 (en) | Antibody against nkp46 and application thereof | |
| KR102819623B1 (ko) | 생물학적 결합 분자를 선택하는 방법 | |
| BR112021005669A2 (pt) | anticorpos contra bcma solúvel | |
| KR102427948B1 (ko) | 다발성 골수종에서 m-단백질 반응의 임상 평가 | |
| TW201734051A (zh) | 抗ｔｍｅｍ－１８０抗體、抗癌劑、及癌之檢查方法 | |
| Masuko et al. | Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein | |
| JP7082112B2 (ja) | 抗ｇｐｒ２０抗体 | |
| CA3070847C (en) | Diagnostic method | |
| US20230393144A1 (en) | Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assays | |
| WO2021147954A1 (zh) | Semg2抗体及其用途 | |
| CA3140488C (en) | Method for selecting biological binding molecules | |
| US20240329048A1 (en) | Antibodies targeting intracellular tumor antigens and methods for identifying both | |
| US20220356244A1 (en) | Method for selecting biological binding molecules | |
| WO2025061149A1 (zh) | 抗gcc抗体、嵌合抗原受体及其用途 | |
| IL322269A (en) | VHH-based NKP46 binding agents | |
| HK1228954A1 (en) | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210705 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221025 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230201 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230302 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7239575 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |